Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06634875 · ClinicalTrials.gov registry record · Phase 2
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
A Phase 2 study of Colorectal Cancer Metastatic, sponsored by Buzzard Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06634875 is a Phase 2 study of Colorectal Cancer Metastatic that is actively recruiting participants, run by Buzzard Pharmaceuticals. The registered enrollment target is 20 participants, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06634875, a Phase 2 study of Colorectal Cancer Metastatic, is actively recruiting participants, sponsored by Buzzard Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
Conditions Studied
Interventions
- DRUG isunakinra
Study Locations (2)
California
- USC/Norris Cancer Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06634875
The ClinicalTrials.gov registry entry for NCT06634875 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 18 other Colorectal Cancer Metastatic trials with a reported enrollment target (90% lower). The listed sponsor is Buzzard Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which isunakinra is the first listed.
NCT06634875 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06634875 about?
NCT06634875 is a clinical study titled "Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)". This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this s...
What is the current status of trial NCT06634875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-01-30. Estimated completion is 2026-12.
What conditions does trial NCT06634875 study?
This clinical trial studies the following conditions: Colorectal Cancer Metastatic.
What interventions are being tested in trial NCT06634875?
The interventions under investigation include: isunakinra (DRUG).
Who is sponsoring clinical trial NCT06634875?
This trial is sponsored by Buzzard Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06634875 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
RECRUITING · Phase 2
-
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
COMPLETED · Phase 2
-
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.